BIO-TECHNE Corp
TECH evidence brief
What we can confirm
- BioSniper Score:
- 6.8 / 10
- Market Cap:
- $11.34B
What it means
What to watch
Prepared research question
What matters most for TECH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TECH
BIO-TECHNE Corp (TECH) is a life sciences company that provides biotechnology tools, reagents, and services to the research and clinical diagnostics markets, with a focus on protein analysis and cell biology.
Key risk: Large contingent payment
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$11.34B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 27 clinical trials for BIO-TECHNE Corp.
BIO-TECHNE Corp (TECH) is a life sciences company that provides biotechnology tools, reagents, and services to the research and clinical diagnostics markets, with a focus on protein analysis and cell biology.
- Cash & equivalents of $264.7M as of 2026-06-30 [sec].
- Shareholders' equity of $2,108.2M as of 2026-06-30 [sec].
- Generated $196.7M cash from operating activities in the nine months ended March 31, 2026 [sec_mda · as of 2026-05-06].
- Management expects to meet cash and working capital requirements for at least the next 12 months through available cash, operations, and credit line [sec_mda · as of 2026-05-06].
What works
- Strong cash position of $264.7M as of 2026-06-30 provides financial flexibility for operations and investments [sec].
- Positive cash flow from operations: $196.7M generated in nine months ended March 31, 2026 [sec_mda · as of 2026-05-06].
- Management expects to meet cash and working capital requirements for at least the next 12 months [sec_mda · as of 2026-05-06].
What to weigh
- A second option payment of approximately $1 billion plus potential contingent consideration is forecasted between fiscal 2026 and fiscal 2028, which could strain cash reserves [sec_mda · as of 2026-05-06].
- As of March 31, 2026, the second milestones for that payment have not been met, creating uncertainty [sec_mda · as of 2026-05-06].
From the filings
Quoted directly from source documents.
Cash generated from operating activities in nine months ended March 31, 2026
“The Company generated cash of $196.7 million from operating activities in the nine months ended March 31, 2026”
SEC MD&A · May 6, 2026
Management expects to meet cash requirements for at least next 12 months
“Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months”
SEC MD&A · May 6, 2026
Risks & what to watch (1)›
Key risks
- Large contingent payment — Second option payment of ~$1 billion plus contingent consideration forecasted between fiscal 2026-2028; milestones not yet met [sec_mda · as of 2026-05-06].
What to watch
- Whether the second milestones for the ~$1 billion option payment are met and how the payment is funded [sec_mda · as of 2026-05-06].
- Cash flow from operations in upcoming quarters to assess ongoing financial health [sec_mda · as of 2026-05-06].
Sources: Catalysts · Competitor trials · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run BIO-TECHNE Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BIO-TECHNE Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.23
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 9.7%
- Days to cover
- 6.6
- Shares short
- 13,338,470
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TECH short interestGovernance
Frequently asked questions
What is the AI investment thesis for BIO-TECHNE Corp?
BIO-TECHNE Corp (TECH) is a life sciences company that provides biotechnology tools, reagents, and services to the research and clinical diagnostics markets, with a focus on protein analysis and cell biology.
Who is the CEO of BIO-TECHNE Corp?
Mr. Kim Kelderman is the chief executive officer of BIO-TECHNE Corp (TECH).
Where is BIO-TECHNE Corp headquartered?
BIO-TECHNE Corp (TECH) is headquartered in Minneapolis, MN, United States.
What therapeutic areas does BIO-TECHNE Corp focus on?
BIO-TECHNE Corp develops therapies across Oncology, Neurology, Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.